欢迎访问行业研究报告数据库

行业分类

当前位置:首页 > 报告详细信息

找到报告 1 篇 当前为第 1 页 共 1

(212)PB /(212)Bi 肽对于靶向转移性黑色素瘤的试验和进展

Development and Testing of (212)Pb/(212)Bi Peptide for Targeting Metastatic Melanoma
作者:Fisher, D. R. 作者单位:Pacific Northwest National Lab., Richland, WA.;Department of Energy, Washington, DC. 加工时间:2014-09-10 信息来源:科技报告(DE) 索取原文[14 页]
关键词:黑素瘤;肽;肿瘤;细胞培养;化疗;诊断(医学)
摘 要:Metastatic melanoma (common skin cancer) develops from malignant transformation of the melanocyte, a cell that produces the pigment melanin. Melanomas spread superficially or systemically by nodular invasion. Metastases spread to regional lymph nodes and then distally to the lungs, liver, bone, and brain, where they grow into large tumor masses. Melanoma, a cell type that is highly radiation-resistant, is treated by wide surgical excision of primary tumors. However, distal symptomatic metastases can only be treated by chemotherapy (dicarbazine, temozolomide, paclitaxel, or cisplatin), which produce low response rates to therapy (15), serious side-effects, and no improvement in overall survival. Current medical treatments are rarely successful, and the prognosis for patients diagnosed with metastatic melanoma is poor (Claveau et al., 2009). The need for improved and more effective therapies against metastatic melanoma is well-confirmed by recent clinical studies. Radiation biologists recognize that alpha particles are effective in killing melanoma cancer cells. High-linear-energy alpha particles can be effective in treating radiation-resistant disease that responds poorly to traditional low-linear-energy beta/gamma emitters (Sgouros et al., 2010). Because of the short range of alpha particles (40 to 70 micrometers in soft tissue), and to be effective in cell killing, the alpha-emitters need to be delivered directly to cancer cells using cell-targeted radioimmunotherapy.
© 2016 武汉世讯达文化传播有限责任公司 版权所有
客服中心

QQ咨询


点击这里给我发消息 客服员


电话咨询


027-87841330


微信公众号




展开客服